US$ 22.56
glp-1 agonist drugs oral receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is NEW: This new oral GLP-1
Description
Back Finan, B, Ma, T, Ottaway, M (20 Oct 2013) 'Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans', Science Translational Medicine , 5/209, 2-9a151
PubMed Central, Eser, Hale Yapici, et al

143: 43974408 [DOI] [PubMed] [Google Scholar] 86.Wang Q, Brubaker PL
As different classes of drugs target different aspects of T2DM via distinct mechanisms of action, a combination of treatments is generally more effective at maintaining glycaemic control than monotherapy over the long term [12]

doi: 10.1016/j.eprac.2023.11.007 64 MoseleyKF

[DOI] [PubMed] [Google Scholar] 35.Findling R.L., Cutler A.J., Saylor K., Gasior M., Hamdani M., Ferreira-Cornwell M.C., Childress A.C